Impact Factor
4.15
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.41
3,725 total citations
h5-index
55
h5 depth signal
Cited share
86.5%
780 of 902
Total citations
3,725
Citation footprint
Metric signal
4.97
External metric anchor
Self-citation
3.3%
124 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
728
Germany
603
China
528
Japan
444
Italy
321
Citing Fields of Research
Cardiology
3,243
Auto-Inflammatory Disorders
212
Diabetes
208
Kidney Diseases
144
Respiratory Support
132
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,737
Articles tracked across the journal lifetime
Indexed publication set
902
780 cited publications
Last 12 months
327
27.3 publications/month
Open access share
99.4%
325 OA publications in the last year
Leading citing country
United States
728 citing publications
Leading citing field
Cardiology
3,243 citing publications
Latest tracked publication
21 October 2026
10 recent records available
Coverage & Indexing History
v4n1, Feb. 2017-
v2n1, 2015-
Active Coverage
Research Focus & Classification
Indexed Subjects
Cardiology
Issuing & Sponsoring Bodies
issuing body
European Society of Cardiology. Heart Failure Association
Broad Categories
Cardiology
MeSH Descriptors
Heart Failure
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1093/eschf/xvag265
Open DOI
Exercise for Older People with Heart Failure and Frailty: Should We Even Try?
The benefits of exercise in older patients with heart failure (HF) and frailty are twofold: (i) improvement in cardiopulmonary capacity, thus reducing HF-related sequelae; (ii) attenuation of decline in physical function, thus improving ...
02
DOI 10.1093/eschf/xvag266
Open DOI
Finerenone versus Steroidal MRAs in Type 2 Diabetes and Chronic Kidney Disease without Prior Heart Failure
Aims: Type 2 diabetes (T2D) and chronic kidney disease (CKD) markedly increase the risk of heart failure (HF) and death. While finerenone improves outcomes in clinical trials, real-world evidence and direct comparisons with steroidal min...
03
DOI 10.1093/eschf/xvag249
Open DOI
Sexual Health in Heart Failure: How Age, Sex, and Dyspnea Interact to Shape Intimacy and Unmet Clinical Needs
Aims: Sexual health is a cornerstone of well-being among the least explored aspects of heart failure (HF) care. Guidelines offer minimal, male-focused recommendations, leaving female sexual health underaddressed. The ROMANT'IC study inve...
04
DOI 10.1093/eschf/xvag256
Open DOI
Prognostic Impact of Moderate Secondary Mitral Regurgitation After Optimized Medical Therapy in Heart Failure
Background: The prognostic significance of moderate secondary mitral regurgitation (MR) after optimized guideline-directed medical therapy (GDMT) in heart failure (HF) remains uncertain. Methods: We analyzed 2,468 ambulatory HF patients ...
05
DOI 10.1093/eschf/xvag259
Open DOI
Age-associated clinical patterns in paediatric myocarditis: left ventricular function as the key early risk stratifier
Background and Aims: In myocarditis, early identification of high-risk patients is essential, robust prognostic markers are lacking. We aimed to identify early clinical risk stratifier at index hospitalization for major adverse cardiovas...
06
DOI 10.1093/eschf/xvag261
Open DOI
Cost-effectiveness of intravenous ferric derisomaltose for patients with heart failure and iron deficiency in the UK based on the IRONMAN trial results
Background and Aims: Iron deficiency is common in patients with chronic heart failure. The IRONMAN trial investigated the effect of intravenous (IV) ferric derisomaltose (FDI) compared to usual care on a composite endpoint of hospitalisa...
07
DOI 10.1093/eschf/xvag254
Open DOI
EARTH-HCM: A Real-World Tool to Visualize the Burden of Hypertrophic Cardiomyopathy in the United States
Background: There is limited evidence on geographical distribution of hypertrophic cardiomyopathy (HCM) disease burden and a lack of visualization of national data for patient outcomes among patients with HCM. Objectives: To evaluate the...
08
DOI 10.1093/eschf/xvag252
Open DOI
Palliative-Oriented Referral and Advanced Vulnerability in Very Old Patients Hospitalised for Acute Heart Failure
Background: Palliative-oriented referral in very old patients hospitalised for acute heart failure (HF) is common in cardiogeriatric practice, but their clinical profile and outcomes remain poorly described. We used referral to the Frenc...
09
DOI 10.1093/eschf/xvag245
Open DOI
Does higher kidney risk justify more finerenone? Reappraising absolute benefit against the safety window of FINEARTS-HF
Chronic kidney disease has long been viewed as a reason for caution when prescribing mineralocorticoid receptor antagonists (MRAs) in heart failure (HF), a doctrine rooted in the safety record of the steroidal agents: in TOPCAT, drug dis...
10
Bibliographical & Catalog Notes
Volume numbering from contents page.
Mode of access: World Wide Web.
Affiliated with: European journal of heart failure 1388-9842 (DLC)sn 99-39900 (OCoLC)43095676 (DNLM)100887595.